Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
about
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic HyperplasiaMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerHeat shock and other apoptosis-related proteins as therapeutic targets in prostate cancerEffect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cellsMolecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?BCL2 genotypes and prostate cancer survival.Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiationA tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratificatTissue biomarkers for prostate cancer radiation therapy."No Turning Bax" in the combined battle against prostate cancer:Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.An improved method for constructing tissue microarrays from prostate needle biopsy specimens.Systematic review of hypofractionated radiation therapy for prostate cancer.The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.Predictive models in external beam radiotherapy for clinically localized prostate cancer.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions.Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.Screening candidate microRNA-mRNA regulatory pairs for predicting the response to chemoradiotherapy in rectal cancer by a bioinformatics approachThe acute lymphoblastic leukemia prognostic scoring whether it is possible by BCL-2, BAX gene promoter genotypingABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cellsMolecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.Systemic Delivery of Bc12-Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth.The relationship between p27(kip1) expression and the change of radiosensitivity of esophageal carcinoma cells.Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
P2860
Q26741226-4FB4799A-63B4-4B67-9D10-0926CF0C525EQ26766638-868D934A-A090-4DA8-A17E-F1A6CA9FFEABQ26778586-C9435F0E-F8C1-48FE-9283-6DA9047FD674Q27026128-44D2C024-BD94-44FB-B1FA-0D1CEEF3102DQ28829353-3CE4FF29-4B65-4F99-A6DC-6DCB5D9C4F00Q33480331-A9BF4949-1353-42C0-8290-1CA5C956F2A6Q33708677-11A380ED-4BF6-4B28-BF9A-EB97628968C2Q34015344-89FA5B74-FF51-4F3E-AA89-BE7F52F42CC5Q34158974-83D5C0A7-9E40-4F6C-B49C-18A0F4485E82Q34986428-C349E248-0871-4DA3-91BC-178C90A1322CQ36133745-186BA668-25A5-4A91-97BB-F2A59E1E7DE3Q36141341-51022C60-8B2C-4BDA-A06D-2B118328922DQ36733907-74EA1C62-4E8A-4D29-A94B-9E12640D6884Q36824013-D3C718AE-78A1-4BF9-A2C6-4E7274365B9AQ37124747-A8C2A43F-64E0-495E-92A4-320906488A59Q37260048-C1C91CF2-591A-4891-B698-0DDD60C80FEEQ37324126-CF580215-B452-4228-BC1C-3D7ABFACFC67Q37376013-9F005137-A1F0-42E6-A44D-66762D7BD34CQ37526758-74E2F0AA-1F70-4EB5-9DF3-AFCEA78D5FA1Q37709925-2E1B3B9D-82DA-4196-B181-8A9E3F277F5CQ37965553-10A4A023-B95F-465F-9D71-EE6B5697EF8FQ38042634-A0FEDC35-3EDE-42F9-BF3D-F682703A190BQ38063121-2E536AAA-5050-4FD0-9440-80713C0A0919Q38207607-C49954BD-3F0F-4350-8367-6E821A1FDD10Q38375214-FFF646EE-E383-4F94-A447-0DFFAB4F372FQ39146064-F1E7560A-52E8-4F97-B4C2-4F6A82930154Q41197547-399D20F6-4F94-40E8-BD10-3EAA11CB4AB6Q41970044-F03DE56D-6354-402B-9CFA-C75AED41C051Q42094231-651B7F7F-AED6-4C23-8346-07850F13A5E4Q42184292-02340D71-65FE-45FA-9844-0CD23FC6A9DBQ47405155-734F05DE-6B90-4FB4-9BB5-7F032E4399BBQ53297264-49B95166-9EBB-4000-9113-8C653F897D0DQ53702234-0C9B2AC3-880E-49FD-B87F-69418CEA06B9
P2860
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@en
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@nl
type
label
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@en
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@nl
prefLabel
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@en
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@nl
P2093
P2860
P1476
Bcl-2 and Bax expression predi ...... oncology group protocol 92-02.
@en
P2093
Alan Pollack
Elizabeth H Hammond
Gerald E Hanks
Howard M Sandler
Jennifer Moughan
Li Yan Khor
Mark A Ritter
Seth A Rosenthal
Tahseen Al-Saleem
Varagur Venkatesan
P2860
P304
P356
10.1158/1078-0432.CCR-06-2972
P407
P577
2007-06-01T00:00:00Z